89 related articles for article (PubMed ID: 16465416)
1. The reactivity to CK5/6 antibody in tumor cells from non-small cell lung cancers shed into pleural effusions predicts survival.
Dejmek JS; Dejmek A
Oncol Rep; 2006 Mar; 15(3):583-7. PubMed ID: 16465416
[TBL] [Abstract][Full Text] [Related]
2. CK5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma.
Dejmek A
Acta Cytol; 2008; 52(5):579-83. PubMed ID: 18833821
[TBL] [Abstract][Full Text] [Related]
3. Intraoperative pleural lavage: is it a valid prognostic factor in lung cancer?
Vicidomini G; Santini M; Fiorello A; Parascandolo V; Calabrò B; Pastore V
Ann Thorac Surg; 2005 Jan; 79(1):254-7; discussion 254-7. PubMed ID: 15620952
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of pleural effusion in patients with non-small cell lung cancer.
Sugiura S; Ando Y; Minami H; Ando M; Sakai S; Shimokata K
Clin Cancer Res; 1997 Jan; 3(1):47-50. PubMed ID: 9815536
[TBL] [Abstract][Full Text] [Related]
5. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.
Pu RT; Pang Y; Michael CW
Diagn Cytopathol; 2008 Jan; 36(1):20-5. PubMed ID: 18064689
[TBL] [Abstract][Full Text] [Related]
6. Sensitive detection of small cell lung carcinoma cells by reverse transcriptase-polymerase chain reaction for prepro-gastrin-releasing peptide mRNA.
Saito T; Kobayashi M; Harada R; Uemura Y; Taguchi H
Cancer; 2003 May; 97(10):2504-11. PubMed ID: 12733150
[TBL] [Abstract][Full Text] [Related]
7. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
Shield PW; Koivurinne K
Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
[TBL] [Abstract][Full Text] [Related]
8. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
9. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas.
Camilo R; Capelozzi VL; Siqueira SA; Del Carlo Bernardi F
Hum Pathol; 2006 May; 37(5):542-6. PubMed ID: 16647951
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions.
Toumbis M; Rasidakis A; Passalidou E; Kalomenidis J; Alchanatis M; Orphanidou D; Jordanoglou J
Anticancer Res; 1996; 16(4A):2101-4. PubMed ID: 8712750
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
Klech H; Rona G; Hutter C; Bayer PM; Kummer F
Wien Klin Wochenschr; 1986 Sep; 98(17):564-73. PubMed ID: 3020811
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
Li CS; Cheng BC; Ge W; Gao JF
Int J Clin Pract; 2007 Mar; 61(3):444-8. PubMed ID: 17313612
[TBL] [Abstract][Full Text] [Related]
15. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Lung Cancer; 2009 Mar; 63(3):410-7. PubMed ID: 18620780
[TBL] [Abstract][Full Text] [Related]
16. Tumor markers as prognostic factors in treated non-small cell lung cancer.
Trapé J; Buxo J; Pérez de Olaguer J; Vidal C
Anticancer Res; 2003; 23(5b):4277-81. PubMed ID: 14666638
[TBL] [Abstract][Full Text] [Related]
17. Pleural lavage cytology before and after lung resection in non-small cell lung cancer patients.
Enatsu S; Yoshida J; Yokose T; Nishimura M; Nishiwaki Y; Shirakusa T; Nagai K
Ann Thorac Surg; 2006 Jan; 81(1):298-304. PubMed ID: 16368385
[TBL] [Abstract][Full Text] [Related]
18. Clinical implication of cyclin B1 in non-small cell lung cancer.
Arinaga M; Noguchi T; Takeno S; Chujo M; Miura T; Kimura Y; Uchida Y
Oncol Rep; 2003; 10(5):1381-6. PubMed ID: 12883711
[TBL] [Abstract][Full Text] [Related]
19. Immunocytochemical panel for distinguishing carcinoma cells from reactive mesothelial cells in pleural effusions.
Wu GP; Zhang SS; Fang CQ; Liu SL; Wang EH
Cytopathology; 2008 Aug; 19(4):212-7. PubMed ID: 18699986
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
